Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell NewsRNAseq was performed on EGFR mutant cell lines treated in vitro with osimertinib and on tumor biopsies of eight EGFR mutant lung cancer patients before and after 2 weeks of tyrosine kinase inhibitorstreatment.
[npj Precision Oncology]
7753456 CVQ8R4JG items 1 apa 0 default asc 1 162480 https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/
%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3A%22zotpress-970b75217abc3d5e08e2eb19466984a2%22%2C%22meta%22%3A%7B%22request_last%22%3A0%2C%22request_next%22%3A0%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%22CVQ8R4JG%22%2C%22library%22%3A%7B%22id%22%3A7753456%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Gurule%20et%20al.%22%2C%22parsedDate%22%3A%222021-05-17%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EGurule%2C%20N.%20J.%2C%20McCoach%2C%20C.%20E.%2C%20Hinz%2C%20T.%20K.%2C%20Merrick%2C%20D.%20T.%2C%20Van%20Bokhoven%2C%20A.%2C%20Kim%2C%20J.%2C%20Patil%2C%20T.%2C%20Calhoun%2C%20J.%2C%20Nemenoff%2C%20R.%20A.%2C%20Tan%2C%20A.%20C.%2C%20Doebele%2C%20R.%20C.%2C%20%26amp%3B%20Heasley%2C%20L.%20E.%20%282021%29.%20A%20tyrosine%20kinase%20inhibitor-induced%20interferon%20response%20positively%20associates%20with%20clinical%20response%20in%20EGFR-mutant%20lung%20cancer.%20%3Ci%3ENpj%20Precision%20Oncology%3C%5C%2Fi%3E%2C%20%3Ci%3E5%3C%5C%2Fi%3E%281%29%2C%201%26%23x2013%3B11.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41698-021-00181-4%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41698-021-00181-4%3C%5C%2Fa%3E%20%3Ca%20title%3D%27Cite%20in%20RIS%20Format%27%20class%3D%27zp-CiteRIS%27%20href%3D%27https%3A%5C%2F%5C%2Fwww.stemcellsciencenews.com%5C%2Fwp-content%5C%2Fplugins%5C%2Fzotpress%5C%2Flib%5C%2Frequest%5C%2Frequest.cite.php%3Fapi_user_id%3D7753456%26amp%3Bitem_key%3DCVQ8R4JG%27%3ECite%3C%5C%2Fa%3E%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22A%20tyrosine%20kinase%20inhibitor-induced%20interferon%20response%20positively%20associates%20with%20clinical%20response%20in%20EGFR-mutant%20lung%20cancer%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Natalia%20J.%22%2C%22lastName%22%3A%22Gurule%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caroline%20E.%22%2C%22lastName%22%3A%22McCoach%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Trista%20K.%22%2C%22lastName%22%3A%22Hinz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Daniel%20T.%22%2C%22lastName%22%3A%22Merrick%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adriaan%22%2C%22lastName%22%3A%22Van%20Bokhoven%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jihye%22%2C%22lastName%22%3A%22Kim%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tejas%22%2C%22lastName%22%3A%22Patil%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jacob%22%2C%22lastName%22%3A%22Calhoun%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Raphael%20A.%22%2C%22lastName%22%3A%22Nemenoff%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aik%20Choon%22%2C%22lastName%22%3A%22Tan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Robert%20C.%22%2C%22lastName%22%3A%22Doebele%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lynn%20E.%22%2C%22lastName%22%3A%22Heasley%22%7D%5D%2C%22abstractNote%22%3A%22Tyrosine%20kinase%20inhibitors%20%28TKIs%29%20targeting%20EGFR-mutant%20lung%20cancers%20promote%20a%20range%20of%20tumor%20regression%20responses%20to%20yield%20variable%20residual%20disease%2C%20a%20likely%20incubator%20for%20acquired%20resistance.%20Herein%2C%20rapid%20transcriptional%20responses%20induced%20by%20TKIs%20early%20in%20treatment%20that%20associate%20with%20the%20range%20of%20patient%20responses%20were%20explored.%20RNAseq%20was%20performed%20on%20EGFR%20mutant%20cell%20lines%20treated%20in%20vitro%20with%20osimertinib%20and%20on%20tumor%20biopsies%20of%20eight%20EGFR%20mutant%20lung%20cancer%20patients%20before%20and%20after%202%20weeks%20of%20TKI%20treatment.%20Data%20were%20evaluated%20for%20gene%20expression%20programs%20altered%20upon%20TKI%20treatment.%20Chemokine%20and%20cytokine%20expression%20were%20measured%20by%20ELISA%20and%20quantitative%20RT-PCR.%20I%5Cu03baB%20Kinase%20%28IKK%29%20and%20JAK-STAT%20pathway%20dependence%20was%20tested%20with%20pharmacologic%20and%20molecular%20inhibitors.%20Tumor%20sections%20were%20stained%20for%20the%20T-cell%20marker%20CD3.%20Osimertinib%20stimulated%20dynamic%2C%20yet%20wide-ranging%20interferon%20%28IFN%29%20program%20regulation%20in%20EGFR%20mutant%20cell%20lines.%20IL6%20and%20CXCL10%20induction%20varied%20markedly%20among%20the%20EGFR%20mutant%20cell%20lines%20and%20was%20sensitive%20to%20IKK%20and%20JAK-STAT%20inhibitors.%20Analysis%20of%20matched%20patient%20biopsy%20pairs%20revealed%20marked%2C%20yet%20varied%20enrichment%20of%20IFN%20transcriptional%20programs%2C%20effector%20immune%20cell%20signatures%20and%20T-cell%20content%20in%20treated%20tumors%20that%20positively%20correlated%20with%20time%20to%20progression%20in%20the%20patients.%20EGFR-specific%20TKIs%20induce%20wide-ranging%20IFN%20response%20program%20activation%20originating%20within%20the%20cancer%20cell.%20The%20strong%20association%20of%20IFN%20program%20induction%20and%20duration%20of%20clinical%20response%20indicates%20that%20the%20TKI-induced%20IFN%20program%20instructs%20variable%20recruitment%20and%20participation%20of%20immune%20cells%20in%20the%20overall%20therapeutic%20response.%22%2C%22date%22%3A%222021-05-17%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1038%5C%2Fs41698-021-00181-4%22%2C%22ISSN%22%3A%222397-768X%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.nature.com%5C%2Farticles%5C%2Fs41698-021-00181-4%22%2C%22deleted%22%3A1%2C%22collections%22%3A%5B%2243ZBJFKZ%22%5D%2C%22dateModified%22%3A%222021-05-17T22%3A46%3A40Z%22%7D%7D%5D%7D
Gurule, N. J., McCoach, C. E., Hinz, T. K., Merrick, D. T., Van Bokhoven, A., Kim, J., Patil, T., Calhoun, J., Nemenoff, R. A., Tan, A. C., Doebele, R. C., & Heasley, L. E. (2021). A tyrosine kinase inhibitor-induced interferon response positively associates with clinical response in EGFR-mutant lung cancer. Npj Precision Oncology, 5(1), 1–11. https://doi.org/10.1038/s41698-021-00181-4 Cite
